LIPA gene mutations affect the composition of lipoproteins: Enrichment in ACAT-derived cholesteryl esters by L. Arnaboldi et al.
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
1 
 
LIPA GENE MUTATIONS AFFECT THE COMPOSITION OF LIPOPROTEINS: 
ENRICHMENT IN ACAT-DERIVED CHOLESTERYL ESTERS 
 
Lorenzo Arnaboldia,1, Alice Ossolib,1, Eleonora Giorgiob, Livia Pisciottac,d, Tiziano Lucchie, 
Liliana Grigoref, Chiara Pavanellob, Agnese Granataa, Andrea Pastac, Beatrice Arosioe,g, 
Domenico Azzolinoe,g, Andrea Baragettia, Samuela Castelnuovoh, Alberto Corsinia,i, Alberico 
L. Catapanoa,i, Laura Calabresib and Monica Gomaraschib,* 
 
a Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, 
Milan, Italy; b Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e 
Biomolecolari, Università degli Studi di Milano, Milan, Italy; c Department of Internal Medicine, 
University of Genova, Italy; d Policlinic Hospital San Martino, Genoa, Italy; e Metabolic Disease 
Clinic - Geriatric Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, 
Italy; f S.I.S.A. Center for the Study of Atherosclerosis, Bassini Hospital, Cinisello Balsamo, 
Italy; g Department of Clinical Sciences and Community Health, University of Milan, Italy; h 
Centro Dislipidemie, ASST Ospedale Niguarda, Milan, Italy; i IRCCS Multimedica Hospital, 
Milan, Italy. 
 
1 co-first authors 
 
* Corresponding author: 
Monica Gomaraschi, PhD 
Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche e Biomolecolari 
Università degli Studi di Milano 
Via Balzaretti 9, 20133 Milano, Italy 
E-mail: monica.gomaraschi@unimi.it 
 
Word count: 3865 
Tables and figures: 1 table and 4 figures. 
Keywords: Cholesteryl ester storage disease; Lysosomal acid lipase; Lipoproteins. 
*Abstract, Title Page, Manuscript, References, Legends
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
ABSTRACT 
Background and aims 
Cholesteryl ester storage disease (CESD) due to LIPA gene mutations is characterized by 
hepatic steatosis, hypercholesterolemia and hypoalphalipoproteinemia, exposing affected 
patients to an increased cardiovascular risk. Further insights into the impact of LIPA gene 
mutations on lipid/lipoprotein metabolism are limited. Aim of the study was to investigate the 
effect of carrying one or two mutant LIPA alleles on lipoprotein composition and function. 
Methods 
Lipoproteins were isolated from 6 adult CESD patients, 5 relatives carrying one mutant LIPA 
allele (carriers) and 12 sex/age matched controls. Lipid profile, lipoprotein mass composition 
and the fatty acid distribution of cholesteryl esters (CEs) were assessed. HDL function was 
evaluated as the ability to promote nitric oxide release by endothelial cells. 
Results 
Despite the lipid-lowering therapy, total cholesterol, LDL-cholesterol and triglycerides were 
increased in CESD patients compared to controls, while HDL-cholesterol was reduced. 
Carriers also displayed elevated total and LDL-cholesterol. Very low and intermediate density 
lipoproteins from CESD patients and carriers were enriched in CEs compared to the control 
ones, with a concomitant reduction of triglycerides. Fatty acid composition of CEs in serum 
and lipoproteins showed a depletion of linoleate content in CESD patients, due to the reduced 
LCAT activity. In CESD HDL, fatty acid distribution of CEs was shifted towards saturated 
ones, if compared to control HDL. The changes in HDL composition did not affect HDL ability 
to promote nitric oxide release by endothelial cells. 
Conclusions 
LIPA gene mutations significantly affected plasma levels and lipid composition of lipoproteins, 
likely contributing to the increased cardiovascular risk of affected patients. 
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1. Introduction 
Lysosomal acid lipase (LAL) is a key regulator of cellular lipid homeostasis; it catalyzes the 
hydrolysis of cholesteryl esters (CEs) and triglycerides (TGs), which are taken up through the 
receptor-mediated endocytosis of apoB-containing lipoproteins, in the lysosomal compartment 
[1]. 
Unesterified cholesterol (UC) and free fatty acids (FFAs) generated by LAL are then released 
in the cytosol, where they can regulate their own synthesis and metabolism. LAL is coded by 
the LIPA gene on chromosome 10, and mutations affecting enzyme expression or function 
cause two recessive autosomal diseases depending on residual LAL activity: Wolman 
disease (WD) and Cholesteryl Ester Storage Disease (CESD) [2]. WD is the most severe 
form of LAL deficiency (LAL-D) with a LAL activity below 1% than normal and results in 
demise in the first year of life for hepatic and adrenal failure. CESD is the later-onset type that 
may present in infancy, childhood or adulthood, with residual LAL activity within 1% and 12% 
than normal values. Clinically, CESD patients present with hepatomegaly, splenomegaly, 
malabsorption and increased cardiovascular risk [3]. Consistently, carotid intima-media 
thickness (cIMT), a marker of preclinical atherosclerosis, is elevated in CESD patients; 
however, a direct comparison with age- and sex-matched controls is lacking [4,5]. 
Biochemically, hypercholesterolemia (variably associated with hypertriglyceridemia) and low 
plasma levels of HDL-cholesterol (HDL-C) have been described, together with elevation of 
liver enzymes [3]. Few studies analyzed carriers of one mutant LIPA allele; even in the 
absence of a clinical phenotype, some alterations of the lipid profile were detected in 
heterozygotes if compared to non carriers [6,7]. 
Clinical and biochemical features of LAL-D are the consequence of the accumulation of CEs 
and, to a lesser extent, TGs in the lysosomes. Since LAL is ubiquitously expressed, lipid 
accumulation occurs in all tissues, but especially in the liver and in macrophages throughout 
the body [3]. Lipid accumulation in the liver causes a peculiar microvescicular steatosis [8,9], 
which can evolve to fibrosis and cirrhosis. Interestingly, the rate of progression of liver 
disease in CESD patients is higher than that of other chronic liver diseases, as NAFLD or 
hepatitis C; indeed, the median time to the first documentation of fibrosis, cirrhosis, or liver 
transplantation was estimated as 3.1 years from the first clinical manifestation of LAL-D [10]. 
In hepatocytes, the lack of UC and FFA release in the cytosol results in the SREBP-mediated 
upregulation of cholesterol and fatty acid synthesis, leading to increased VLDL secretion and 
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hypercholesterolemia [11-13]. The complex alterations of lipid metabolism induced by LAL-D, 
including the inhibition of ABCA1 expression with a reduced HDL biogenesis, also lead to the 
low plasma levels of HDL-C observed in CESD patients [14]. 
Further insights into the impact of genetic LAL-D on the structural and functional features of 
the different lipoprotein classes are limited. In particular, since CEs play a central role in the 
pathology of LAL-D, it would be relevant to known whether the content of CEs is altered in 
CESD lipoproteins; in addition, understanding which esterification system is mainly 
responsible for CE synthesis could provide the rationale for the development of novel 
therapeutic strategies for LAL-D. The esterification of cholesterol can occur intracellularly or 
within the plasma compartment. Acyl-coenzyme A:cholesterol acyltransferase (ACAT) is 
located in the endoplasmic reticulum and catalyzes the synthesis of CEs in the cytosol by 
conjugating cholesterol to long-chain fatty acids, mainly oleic and palmitic acids [15]. On the 
contrary, lecithin:cholesterol acyltransferase (LCAT) is the only enzyme responsible for CE 
generation in plasma; it acts on cholesterol carried by all lipoprotein classes and unsaturated 
FAs are its preferred substrates, especially linoleate [16]. Unfortunately, being ACAT an 
intracellular enzyme, its expression and activity cannot be easily evaluated in blood samples, 
as for LCAT; however, it is possible to infer ACAT and LCAT contribution to CE generation by 
evaluating CE fatty acid composition [17-19]. 
Regarding the impact of genetic LAL-D on lipoprotein function, we previously showed that 
cholesterol efflux capacity of HDL is impaired in CESD patients [20]. It is well known that 
atheroprotection by HDL is also mediated by several activities that are independent from their 
role in cholesterol transport, as the ability to preserve endothelial homeostasis [21]. In this 
context, the ability of HDL to promote the release of nitric oxide (NO) from endothelial cells is 
a widely used and reproducible assay of HDL function [22]. No evidence of the impact of 
genetic LAL-D on endothelial protection by HDL is available.  
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2. Materials and Methods 
2.1 Patients, Carriers and Controls 
Blood samples were collected from 6 CESD patients. Cases 1 and 2 were twins carrying the 
c.894 G>A (p.S275_Q298) and c.652 C>T (p.R218X) LIPA gene mutations. Case 3 was 
compound heterozygote for the c.894 G>A (p.S275_Q298) and the c.883C>T (p.H295Y) 
mutations. Case 4 was compound heterozygote for the c.652 C>T (p.R218X) and c.881 T>C 
(p.L294S) mutations. Case 5 was homozygote for the c.894 G>A (p.S275_Q298) mutation. 
All CESD patients presented with hypercholesterolemia, elevated transaminases and hepatic 
steatosis (Supplemental table 1) [4,23-25]. Case 6 was homozygote for the c.894 G>A 
(p.S275_Q298) mutation and heterozygote for the c.137T>C (p.L46P) mutation in the APOE 
gene [26]; interestingly, she displayed hypercholesterolemia with low HDL-C, but normal 
transaminases and no sign of hepatic steatosis (Supplemental table 1). All cases were on 
lipid-lowering therapy; none was treated with enzyme replacement therapy at the time of 
analysis (Supplemental table 1). 
Five carriers of one mutant LIPA allele, hereafter referred to as “carriers”, were enrolled 
among cases’ parents (n=4) or during the screening for the c.894 G>A mutation (n=1). One 
subject carried the c.652 C>T (p.R218X) mutation and four subjects carried the c.894 G>A 
(p.S275_Q298) LIPA gene mutation. Two carriers were on statin therapy. 
A group of healthy subjects, matched for sex and age at a 2:1 ratio to CESD patients, was 
enrolled. 
Carotid IMT measurements were performed by high-resolution B-mode carotid 
ultrasonography as previously described [27]. Briefly, the far walls of the left and right 
common carotids, bifurcations, and internal carotids were visualized in anterior, lateral, and 
posterior projections. Images were saved as JPEG files on a digital support. Carotid IMT 
measurements were performed using a dedicated software that allows semiautomatic edge 
detection of the echogenic lines of the intima-media complex (M'Ath, Metris S.R.L., France). 
All carotid measurements were averaged to calculate the mean IMT for each subject. The 
study conformed to the guidelines set out in the Declaration of Helsinki and was approved by 
the ethical committee of Milano Area C (n. 582-112015); all enrolled patients gave written 
informed consent for participation in the study. 
 
2.2 Biochemical analyses 
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Blood samples were collected after an overnight fast. Plasma levels of total cholesterol (TC), 
TGs, HDL-C, apolipoprotein A-I and B, aspartate aminotransferase, alanine 
aminotransferase, and gamma glutamyltransferase were measured by certified enzymatic 
and immunoturbidimetric assays on a c311 automatic analyzer (Roche Diagnostics). LDL-
cholesterol (LDL-C) was calculated by the Friedewald formula. 
LCAT activity was measured as the ability of endogenous LCAT to esterify cholesterol 
incorporated into an exogenous standardized substrate [28]. The substrate was a 
reconstituted HDL (rHDL) made of apoA-I, palmitoyloleylphosphatidylcholine and cholesterol 
at a weight ratio of 1:2.17:0.11 (corresponding to a molar ratio of 1:80:8), prepared by the 
cholate dialysis technique [29]. Plasma and rHDL were mixed at a 1:10 volume ratio and 
incubated for 1h at 37°C. UC was measured before and after the incubation by a standard 
enzymatic assay in the absence of cholesterol esterase. Absorbance at 510 nm was 
measured with a Synergy H1 multi-mode reader (BioTek). 
LAL activity on dried blood spots (DBS) was measured by fluorescence using 4-
methylumbelliferone palmitate (Cayman Chemicals), cardiolipin (Avanti Polar Lipids) and the 
selective LAL inhibitor Lalistat 2 (kindly provided by Alexion Pharma), according to the 
method of Hamilton et al. [30]. The generation of fluorescent 4-methylumbelliferone (4-MU) 
was detected by the Synergy H1 Multi-Mode microplate reader and GEN5 software (BioTek). 
LAL activity was calculated by subtracting the activity in the inhibited reaction (with Lalistat 2) 
from uninhibited reaction (with H2O) and expressed as nmols of generated 4-MU/spot/h. 
Normal values of LAL activity are >0.80 nmol/spot/h. 
 
2.3 Lipoprotein isolation and composition 
VLDL (d<1.006 g/ml), IDL (d=1.006-1.020 g/ml), LDL (d=1.020-1.063 g/ml) and HDL 
(d=1.063-1.21 g/ml) were isolated by sequential ultracentrifugation from the plasma of CESD 
patients, carriers and controls. TC, UC, TG and phospholipid (PL) content of the isolated 
lipoproteins was measured by standard enzymatic techniques; the CE mass was calculated 
as (TC – UC) x 1.68. Protein content was assessed by the method of Lowry. Lipoprotein 
composition was expressed as absolute values and as percentage of particle total mass. For 
each lipoprotein, total mass was calculated as the sum of protein, PL, TG, UC and CE 
concentrations. 
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2.4 Cholesteryl ester fatty acid composition 
Serum and lipoprotein samples underwent multiple extractions at 4°C with 
chloroform/methanol 2:1, butylated hydroxytoluene (BHT) 0.01% as antioxidant, and KCl 
0.05%. The pooled organic phases were dried under a stream of nitrogen and resuspended in 
chloroform/methanol 2:1 with BHT. Aliquots were loaded onto a TLC developed in 
hexane:diethylether:acetic acid 80:20:1. After run, TLCs were sprayed with 
dichlorofluorescein and the spots corresponding to CEs were removed. CEs underwent 
derivatization with methanolic HCl 3N for 120 minutes at 80°C, and extraction by 
hexane/water. CE fatty acid (CEFA) content was analyzed by a DANI 1000 GLC (Dani, 
Milano, Italy) equipped with a flame ionization detector and a HTA autosampler (HTA, 
Brescia, Italy) [31]. FA peaks were identified by comparing their retention times with a 
standard mixture (FAME MIX 37, Sigma-Aldrich) and the area under the curve (AUC) was 
determined by automated integration with a dedicated software (Clarity, Prague, Czech 
Republic). Fatty acid composition of CEs is reported as percentage of total AUC. Only for 
sera, TG spots were also removed after TLC and their fatty acid composition was assessed 
as described above.  
 
2.5 NO production in endothelial cells 
Sera from CESD patients, carriers and controls were incubated with 20% polyethylene glycol 
for 20 minutes to precipitate apoB-containing lipoproteins [32]. ApoB-depleted (apoB-D) sera 
were tested for their ability to promote NO production in human umbilical vein endothelial cells 
(HUVECs, PromoCell, Carlo Erba Reagents). NO production was evaluated as previously 
described [33]. Briefly, HUVECs were incubated with 5% (v/v) apoB-D sera for 30 minutes 
and NO generation was detected by fluorescence using diacetate 4,5-diaminofluorescein 
(DAF-2 DA, Sigma-Aldrich Chemie). Fluorescence intensity was measured with a Synergy H1 
Multi-Mode microplate reader equipped with the GEN5 software (BioTek). For each sample, 
fluorescence was normalized by the protein concentration of the total cell lysate. To address 
the equivalence between apoB-D sera and isolated HDL as inducers of NO, HUVECs were 
incubated with apoB-D sera or isolated HDL from controls and NO generation was assessed 
as described above. 
 
2.6 Statistical analysis 
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Data are expressed as mean±SD, if not otherwise stated. Comparisons between groups were 
performed by one-way ANOVA for independent samples. Non-normally distributed variables 
were log-transformed before proceeding to the analysis. Tests were two-sided and p values 
<0.05 were considered as statistically significant. Differences in carotid IMT between CESD 
patients and controls were assessed by covariance analysis (ANCOVA) and adjusted for age, 
sex and plasma lipids. NO production by HDL or by apoB-D sera were compared by Pearson 
correlation. Statistical analysis was performed using SPSS version 24.0 software (SPSS Inc., 
Chicago, USA). 
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3. Results 
3.1 Biochemical and clinical features of CESD patients, carriers and controls 
CESD patients, carriers and controls were comparable for gender distribution and age on 
average (Table 1). LAL activity was almost undetectable in CESD patients; carriers also 
displayed a significant reduction of LAL activity, well below the lower reference limit of 0.8 
nmol/spot/h (Table 1). Controls displayed normal LAL activity values. 
Despite the lipid-lowering therapy, plasma levels of TC, LDL-C, TG and apoB were 
significantly elevated in CESD patients if compared to controls (Table 1). Interestingly, 
carriers also displayed higher plasma levels of TC, LDL-C and apoB than controls, even when 
adjusted for age and sex. HDL-C and apoA-I levels were reduced only in CESD patients. As 
expected, plasma levels of liver transaminases were significantly higher in CESD patients 
than in carriers and controls. Overall, a gene-dose-dependent increase of LDL-C, TG, apoB, 
alanine aminotransferase and gamma glutamyltransferase was detected. 
Mean carotid IMT tended to be higher in CESD patients compared to controls (0.75±0.19 vs 
0.61±0.13 mm, p=0.054), and the difference became significant after adjustment for sex and 
age (Fig. 1, pANCOVA=0.005). Further adjustment for TC, LDL-C or TG did not affect the 
relationship between IMT and LIPA genotype (pANCOVA=0.008, 0.009 and 0.006, respectively); 
on the contrary, the difference was lost after adjustment for HDL-C (pANCOVA=0.223). 
 
3.2 Lipoprotein composition 
Absolute and percentage lipoprotein compositions are reported in Supplementary table 2 and 
Figure 2, respectively. VLDL and IDL percentage compositions were significantly affected by 
the presence of LIPA gene mutations (Fig. 2). VLDL from CESD patients showed a higher 
content of CEs than control VLDL (13.8±1.9% vs 6.7±3.3%, respectively p<0.001), with a 
concomitant reduction of TG content (53.3±4.4% vs 63.1±5.2%, p=0.002). PL content was 
also increased from 13.4±3.0% in control VLDL to 18.7±3.9% (p=0.006) in CESD VLDL. 
These changes were even more evident in IDL: CEs increased from 17.2±6.7% in control IDL 
to 28.7±4.1% in CESD IDL (p=0.002). In addition, TGs were almost halved in CESD IDL 
(21.3±7.8% vs 39.5±7.5% in control IDL, p=0.019). PL content was also significantly higher in 
CESD IDL compared to the control ones (23.5±5.4% vs 16.4±4.0%, respectively). 
Interestingly, the percentage compositions of VLDL and IDL from carriers of one mutant LIPA 
allele were almost identical to those of CESD lipoproteins. Consistently, the absolute content 
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of CEs in VLDL and IDL was significantly higher in CESD patients and carriers compared to 
controls (Supplementary table 2); here, the concomitant higher concentrations of proteins and 
PLs suggest an increased number of circulating VLDL and IDL particles in CESD patients. 
The percentage compositions of LDL and HDL did not show major changes among CESD 
patients, carriers and controls (Fig. 2). 
 
3.3 CEFA composition of plasma and lipoprotein fractions 
The fatty acid composition of CEs accumulating in the lipoproteins of CESD patients was then 
assessed (Supplemental Table 3). A tendency towards a reduction of CEs containing 18:2 
with a mild increase of those containing 18:1 was observed in sera from CESD patients (Fig. 
3). To exclude a possible role of the diet, TG fatty acid composition was also assessed; no 
significant changes were detected between CESD patients, carriers and controls 
(Supplemental Table 4). 
Even if serum CEFA profile was mainly representative of the LDL composition, a significant 
reduction in the percentage content of 18:2 was also observed in CESD VLDL and HDL, 
again with a gene-dose-dependent trend (Fig. 3). When compared to lipoproteins from 
controls, 18:2 content was 8.9% lower in VLDL, 7.4% lower in LDL and 12.5% lower in HDL 
isolated from CESD patients. CESD HDL also displayed a significantly higher content of 16:0 
than control HDL (16.9±2.6% vs 12.3±1.5%, respectively) (Fig. 3). Consequently, in CESD 
HDL the percentage distribution of CEs containing saturated, monounsaturated or 
polyunsaturated fatty acids was shifted towards the saturated ones, if compared to control 
HDL profile (Fig. 4A). No significant changes were detected in VLDL and LDL (data not 
shown). 
The reduced content of 18:2 affected the CE oleate/linoleate ratio in the three main lipoprotein 
classes: a gene-dose dependent increase of the 18:1/18:2 ratio was observed in lipoproteins 
from subjects carrying mutations in the LIPA gene when compared to control ones, consistent 
with what observed on whole sera (Supplemental table 5). The reduced 18:2 content of CE 
and the higher oleate/linoleate ratio observed in carriers of LIPA gene mutations were likely 
due to a reduced cholesterol esterification by LCAT. Indeed, LCAT activity was significantly 
lower in CESD patients compared to controls, with a mean reduction of 38.0±9.3% 
(Supplementary figure 1). 
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3.4 NO production in HUVECs 
Since the CEFA composition of HDL was significantly affected by LIPA gene mutations, the 
impact of this alteration on HDL ability to promote NO production in endothelial cells was 
tested. The increased content of CEs carrying saturated fatty acid residues did not affect NO 
production by HDL; indeed, similar NO levels were detected in cells incubated with apoB-D 
sera from CESD patients, carriers and controls (Fig. 4B). 
HDL ability to promote NO production was assessed using apoB-D sera added to endothelial 
cells at 5% (v/v). Indeed, the incubation of HUVECs with isolated HDL or with apoB-D sera at 
the same final HDL-C concentration induced a comparable increase of NO production 
(Supplemental Figure 2). The equivalence between isolated HDL and apoB-D serum was 
further tested in a wide range of concentrations. When individual apoB-D sera were added at 
a final volume between 2% and 30%, NO generation reached a maximum at 5% and 
decreased at higher concentrations; at 30%, apoB-D sera had no effect on NO generation 
(Supplemental Figure 3). Again, no differences were detected between apoB-D sera and 
isolated HDL in the whole concentration range. When all the data were analyzed together, a 
significant positive correlation was found between the two methods (R=0.794, p<0.001, 
Supplemental Figure 4). 
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4. Discussion 
Cholesteryl ester storage disease is associated with hypercholesterolemia, 
hypoalphalipoproteinemia and possibly hypertriglyceridemia [3], indicating that circulating 
levels of pro-atherogenic lipoproteins are increased, while atheroprotective HDL are reduced. 
Thus, CESD patients are exposed to an increased cardiovascular risk. Indeed, we showed 
that CESD patients had higher carotid IMT values, index of pre-clinical atherosclerosis, than 
controls. Consistently, although in the absence of a direct comparison with matched controls, 
carotid IMT values of CESD patients were found to be >75th percentile of the general 
population with similar age and sex [4,5]. 
We extended previous observations on genetic LAL-D by characterizing its impact on 
lipoproteins composition not only in CESD patients, but also in carriers of one mutant LIPA 
allele belonging to the same families. We showed that the number of circulating apoB-
containing lipoproteins is likely increased, consistent with the higher hepatic secretion of 
VLDL in LAL-D [13]; in addition, lipoprotein composition is altered. In particular, the core of 
VLDL is enriched in CEs and depleted in TGs. This alteration is even more evident in IDL. 
The reduced TG content of VLDL and IDL could be the consequence of an altered 
composition of VLDL during their hepatic assembly, coupled with a preserved TG hydrolysis 
by lipoprotein lipase. Interestingly, the composition of VLDL and IDL is similarly modified in 
heterozygous carriers, thus indicating that a ~50% inhibition of LAL enzymatic activity is 
enough to affect lipoprotein composition. These results imply that the higher content of CEs in 
apoB-containing lipoproteins could contribute to the lipid accumulation in the arterial wall and 
to the accelerated development of atherosclerosis observed in CESD patients. Then, the fatty 
acid composition of CEs was assessed with the aim to investigate their origin. Indeed, CEs  
are produced intracellularly by ACAT and included into nascent VLDL, or are generated in the 
plasma compartment by LCAT. The latter hypothesis was not supported by the significant 
reduction of linoleate (18:2), the preferred LCAT substrate [16], and of LCAT activity in CESD 
patients. Interestingly, the values of LCAT activity detected in CESD patients were similar to 
those of heterozygous carriers of LCAT mutations [34] and to those of patients with chronic 
kidney disease, in which an acquired LCAT deficiency was previously described [35]. The 
cause of LCAT impairment in LAL-D are presently unknown, but it could be the consequence 
of a defective LCAT production by the liver, a key target organ of LAL-D pathology. 
Consequently, it is possible to speculate on a relevant role of ACAT in the generation of CEs 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
accumulating in CESD lipoproteins. The inhibition of ACAT was previously shown to reduce 
hepatic and intestinal accumulation of CEs in animal models of lysosomal storage disorders, 
as LAL-D and Niemann-Pick C disease [36,37]. Our results suggest a possible additional role 
of ACAT in LAL-D pathology by affecting lipoprotein composition and atherosclerosis 
development, which is worth of confirmation in dedicated studies. The reduction of linoleate 
content in CEs was also evident in the other lipoprotein classes, as LDL and HDL; 
consequently, CE linoleate content was reduced in CESD sera, leading to a gene-dose-
dependent increase of the oleate/linoleate ratio. Although limited by the small sample size, 
our results improve the current knowledge on how a reduced LAL activity (and the 
consequent cellular compensatory mechanisms) can affect the lipid/lipoprotein profile of LAL-
D patients. Even if TG fatty acid composition was similar between cases and controls, the 
impact of individual dietary habits on CEFA composition cannot be excluded, due to the lack 
of controls belonging to the same families and of a detailed nutritional assessment of enrolled 
subjects. 
The impact of genetic LAL-D on HDL was investigated to extend our previous observations in 
a smaller group of pediatric CESD patients [20]. CESD HDL had a higher content of CEs 
containing saturated fatty acids in place of those containing polyunsaturated ones. In addition, 
HDL mass composition was characterized by a slight decrease of CEs and by a higher 
protein content, in line with our previous findings of smaller HDL in CESD patients [20]. Thus, 
genetic LAL-D not only impairs HDL biogenesis by the liver [14], but also affects HDL 
composition and subclass distribution. To address the impact of these changes on HDL-
mediated atheroprotection, their ability to promote nitric oxide release by endothelial cells was 
investigated, as a key process in endothelial homeostasis [21]. The results showed that 
CESD HDL fully retained their ability to stimulate nitric oxide release by endothelial cells in 
vitro. On the contrary, we previously showed that HDL ability to promote cell cholesterol 
efflux, the first step of the reverse transport of cholesterol from peripheral tissue to the liver 
[38], is impaired in CESD patients, with an impact on all the tested efflux pathways [20]. This 
partial impairment of HDL function could contribute to the increased cardiovascular risk of 
CESD patients. Consistently, the difference in carotid IMT between CESD patients and 
controls was lost after adjustment for HDL-C. 
The characterization of the lipid/lipoprotein profile in genetic LAL-D was extended to carriers 
of one mutant LIPA allele. Consistent with previous findings [6,7], the lipid profile of these 
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carriers is altered if compared to controls; indeed, a gene-dose-dependent effect of LAL-D 
was observed on plasma LDL-C levels and liver enzymes, but not on HDL-C. Together with 
the altered composition of carriers’ lipoproteins, these findings indicate that even partial LAL-
D can affect plasma lipid/lipoprotein profile. Thus, even if LAL-D is classified as a recessive 
disease and heterozygosity for LIPA gene mutations was not associated to an increased risk 
of cardiovascular events [39], further studies are needed to assess whether carrying one 
mutant LIPA allele could predispose to hepatic and/or atherosclerotic disease in the presence 
of other risk factors. 
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FIGURE LEGENDS 
Fig. 1. Mean carotid intima-media thickness (IMT) in CESD and controls. Values were 
adjusted for age and sex. Data are mean±SEM, n=6 for CESD and 12 for controls. *p<0.05 by 
ANCOVA. 
 
Fig. 2. Lipoprotein composition. Mass percentage composition of lipoproteins isolated by 
ultracentrifugation from the plasma of CESD patients, carriers and controls. Data are 
expressed as mean±SD, n=6 for CESD, 5 for carriers and 12 for controls. *p<0.05 vs controls. 
PL, phospholipids; TG, triglycerides; UC, unesterified cholesterol; CE, cholesteryl esters. 
 
Fig. 3. CEFA composition. Percentage composition of fatty acids in CEs from serum and 
lipoproteins of CESD patients, carriers and controls. Data are expressed as mean±SD, n=6 
for CESD, 5 for carriers and 12 for controls. *p<0.05 vs controls. 16:0, palmitate; 18:1, oleate; 
18:2, linoleate. 
 
Fig. 4. HDL composition and function. (A) Percentage distribution of saturated (SFA), 
monounsaturated (MUFA) and polyunsaturated (PUFA) fatty acids in the CEs of HDL from 
CESD, carriers and controls. (B) NO production in HUVECs. Endothelial cells were incubated 
with 5% (v/v) apoB-depleted sera from CESD patients, carriers and controls to promote NO 
production. Results are expressed as fold of increase in treated vs untreated cells. 
Data are expressed as mean±SD, n=6 for CESD, 5 for carriers and 12 for controls. *p<0.05 
vs controls. 
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Table 1 
Biochemical features of CESD patients, carriers and controls 
 CESD Carriers Controls p 
N (m/f) 6 (1/5) 5 (2/3) 12 (2/10) 0.535 
Age, y 37.7±21.2 58.6±17.9 36.5±18.1 0.149 
LAL activity, nmol/spot/h 0.01±0.01*# 0.57±0.26* 1.35±0.37 <0.001 
Total cholesterol, mg/dl 173.5±33.8* 182.0±32.3* 145.8±11.7 0.015 
Triglycerides, mg/dl 105.3±47.0* 81.3±16.4 57.0±14.1 0.006 
LDL-cholesterol, mg/dl 121.5±26.7* 105.2±29.1* 80.0±15.5 0.003 
HDL-cholesterol, mg/dl 31.0±10.1*# 62.0±10.9 56.5±14.8 0.001 
Apolipoprotein B, mg/dl 111.8±22.9*# 92.2±19.2* 66.1±7.5 <0.001 
Apolipoprotein A-I, mg/dl 87.2±17.0*# 130.2±13.6 127.5±23.0 0.001 
Alanine aminotransferase, U/l 64.2±31.2*# 18.0±7.5 8.9±4.9 <0.001 
Aspartate aminotransferase, U/l 48.8±11.5*# 19.1±3.9 21.6±5.0 <0.001 
Gamma glutamyltransferase, U/l 40.1±33.0*# 17.9±6.0 10.1±2.0 0.007 
Data are expressed as mean±SD, if not otherwise stated. *p<0.05 vs controls and #p<0.05 vs 
carriers for one-way ANOVA or chi-square. p for trend are reported. LAL, lysosomal acid 
lipase.
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